Chronic Disease Prevalence : Rising global rates of type 2 diabetes and obesity are expanding the patient pool for GLP1 therapies, increasing demand for both glycemic and weight management indications
As research continues Read More When GLP-1 Therapy Plateaus: What Clinicians Should Do Next May 13, 2026 Articles, Blood Glucose Control, Blood Glucose Control, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity, Type 2 Diabetes, Type 2 Diabetes 2,554 views Everything seems to be working perfectly until it suddenly isnt
1 The main analysis included all people who started treatment, regardless of any gaps in their therapy, while a sensitivity analysis evaluated outcomes only in people who did not have any gaps in their treatment lasting more than 30 consecutive days
Five steps to successfully implement and evaluate propensity score matching in clinical research studies
Seghal added that the findings are not definitive: "We can't say that GLP-1s are actually causing these symptoms." Copyright 2026 Nexstar Media, Inc
Review Article OPEN ACCESS Lun-Gen Lu * Author information Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with adverse outcomes such as cirrhosis, malignancy, transplantation, and mortality